Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ágnes Salamon"'
Autor:
Gábor Horváth, Ágnes Milassin, Zsolt Szinku, Lilla Lakner, Róbert Sike, Zoltán Szepes, András Lajos Szijártó, Laszlo Lakatos, Károly Palatka, Kata Szántó, István Rácz, Klaudia Farkas, Renáta Bor, Anna Fábián, Árpád V. Patai, Ágnes Salamon, Tibor Nyári, Tamás Molnár, Gábor Tamás Tóth, Krisztina Sarang, Valéria Kovács, Imre Szabó, Andrea Szabó, Mariann Rutka
Publikováno v:
Journal of Gastroenterology and Hepatology Research. 7:2754-2758
OBJECTIVES: Inflammatory bowel diseases are lifelong illnesses and have a huge impact on the quality of life and workability. Although the fully human anti-tumor necrosis factor-alpha, adalimumab provides great opportunity to use biological therapy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fda09585a3acce161cd1ac42cb61e339
https://doi.org/10.17554/j.issn.2224-3992.2018.07.769
https://doi.org/10.17554/j.issn.2224-3992.2018.07.769
Autor:
Pál Miheller, Karin Malíčková, Ágnes Milassin, Tamas Szamosi, Zoltán Szepes, Katarina Mitrova, Milan Lukas, Krisztina Gecse, Zsuzsanna Kurti, Árpád V. Patai, Martin Kolar, Áron Vincze, Anita Bálint, Zsuzsanna Vegh, Klaudia Farkas, Károly Palatka, Peter L. Lakatos, Martin Bortlik, Anna Fábián, Dana Duricova, Laszlo Lakatos, László Bene, Tunde Kristof, Ferenc Nagy, Beáta Gasztonyi, Gábor Tamás Tóth, Renáta Bor, Ágnes Salamon, János Banai, Veronika Hruba, Tamás Molnár, Martin Lukas, Mariann Rutka
Publikováno v:
Expert opinion on drug safety, 16(8), 885-890. Taylor and Francis Ltd.
Background: Safety data of the ‘real life’ use of an infliximab biosimilar, CT-P13 in inflammatory bowel disease (IBD) are still lacking. Our aim was to assess the frequency and characteristics of infusion reactions during CT-P13 therapy in 13 Hu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5150bea4628cea5e9817de3afdf5a78f
https://doi.org/10.1080/14740338.2017.1323330
https://doi.org/10.1080/14740338.2017.1323330
Autor:
Judit Bajor, Anna Fábián, Ágnes Salamon, Kata Szántó, Tamas Szamosi, Mária Matuz, Ferenc Zsigmond, Eszter Schafer, Lilla Lakner, Klaudia Farkas, Károly Palatka, Tamás Molnár, Ágnes Milassin, Mária Papp, Renáta Bor, Áron Vincze, Gábor Horváth, Mariann Rutka, Ferenc Nagy, Anita Bálint, Katalin Müllner, Patrícia Sarlós, Zoltán Szepes, Pál Miheller, Krisztina Sarang, Tibor Tóth
Publikováno v:
Expert opinion on biological therapy. 20(2)
Background: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn’s disease (CD) and ulcerative colitis (UC).Research design and methods: Aim of this study was to determ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e94fc87925c85a67f36ed1e9c76b609
https://pubmed.ncbi.nlm.nih.gov/31782939
https://pubmed.ncbi.nlm.nih.gov/31782939
Autor:
Beáta Gasztonyi, Ágnes Salamon, Tamas Szamosi, Zsuzsanna Vegh, Petra A. Golovics, Zsuzsanna Kurti, Edina Bíró, Zoltán Szepes, Mariann Rutka, Áron Vincze, Laszlo Lakatos, Károly Palatka, Árpád V. Patai, Pál Miheller, Gábor Tamás Tóth, László Bene, Lorant Gonczi, Klaudia Farkas, Krisztina Gecse, Mária Papp, Tunde Kristof, Tamás Molnár, Renáta Bor, Peter L. Lakatos, Barbara D. Lovasz
Publikováno v:
Journal of Crohn's and Colitis, 11(6), 697-705. Elsevier
Background and Aims: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short- and medium-term clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412291c72fa4753d8db729ffaabff2ac
http://www.scopus.com/inward/record.url?scp=85029301295&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85029301295&partnerID=8YFLogxK
Autor:
A Gelley, Zsolt Barta, Anna Fábián, T Molnár, Károly Palatka, Ágota Kovács, Zoltán Szepes, Kata Szántó, Anita Bálint, Klaudia Farkas, Á Vincze, Ágnes Milassin, N Szigeti, Gábor Veres, Mária Papp, Zsuzsanna Erdelyi, E Schafer, Lilla Lakner, Pál Miheller, Tamas Szamosi, Renáta Bor, J Novák, A Zaránd, Péter Lakatos, János Banai, Patrícia Sarlós, Mariann Rutka, Ferenc Nagy, Laszlo Lakatos, Zsuzsanna Kurti, Ágnes Salamon
Publikováno v:
Journal of Crohn's and Colitis. 13:S380-S381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0bf3b2e01bffddb2d992f594936f85b
https://doi.org/10.1093/ecco-jcc/jjy222.658
https://doi.org/10.1093/ecco-jcc/jjy222.658
Autor:
Árpád V. Patai, Zsuzsanna Vegh, Laszlo Lakatos, Zsuzsanna Kurti, László Bene, Beáta Gasztonyi, Ágnes Salamon, Balázs Szalay, Tamas Szamosi, János Banai, Mariann Rutka, Tamás Molnár, Mária Papp, Pál Miheller, Klaudia Farkas, Krisztina Gecse, Zoltán Szepes, Peter L. Lakatos, Gábor Tamás Tóth, Tunde Kristof, Ferenc Nagy, Áron Vincze, Károly Palatka, Barbara D. Lovasz, Lorant Gonczi, Petra A. Golovics
Publikováno v:
Inflammatory bowel diseases, 23(11), 1908-1915. John Wiley and Sons Inc.
Background: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d036a098c5d7e82f0d9aeb84df20c04c
https://pure.amc.nl/en/publications/longterm-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort(c4986fb7-037f-4289-a195-61ac4f749e98).html
https://pure.amc.nl/en/publications/longterm-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort(c4986fb7-037f-4289-a195-61ac4f749e98).html
Autor:
Ágnes Milassin, E Schafer, Pál Miheller, Károly Palatka, Mariann Rutka, Zoltán Szepes, Renáta Bor, Anna Fábián, Ágnes Anna Csontos, Patrícia Sarlós, Kata Szántó, K Sarang, Anita Bálint, Katalin Müllner, T Molnár, Zsuzsanna Vitális, Ágnes Salamon, Tamas Szamosi, F Klaudia, Ferenc Nagy, Lilla Lakner, Mária Papp, Á Vincze, Petra A. Golovics
Publikováno v:
Journal of Crohn's and Colitis. 12:S034-S035
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c2711ce163ae31abc66e8fab48967e7
https://doi.org/10.1093/ecco-jcc/jjx180.044
https://doi.org/10.1093/ecco-jcc/jjx180.044
Autor:
A Gelley, Á Vincze, P Fritz, A. Szepes, Zsuzsanna Erdelyi, Renáta Bor, E Schafer, Zsolt Barta, Zoltán Szepes, Tamas Szamosi, Péter Lakatos, T Molnár, Márk Juhász, Mária Papp, János Banai, Anita Bálint, Katalin Müllner, Ágnes Milassin, Ferenc Nagy, Patrícia Sarlós, Mariann Rutka, Gábor Veres, Anna Fábián, Klaudia Farkas, N Szigeti, Károly Palatka, Ágota Kovács, A Zaránd, O Kadenczki, Laszlo Lakatos, Ágnes Salamon, J Novák, Pál Miheller
Publikováno v:
Journal of Crohn's and Colitis. 12:S540-S541
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30ab988bf17db21ae2a93349e701e15f
https://doi.org/10.1093/ecco-jcc/jjx180.967
https://doi.org/10.1093/ecco-jcc/jjx180.967
Autor:
Bálint Fekete, László Herszényi, Orsolya Terjék, Peter L. Lakatos, Zsolt Tulassay, Ágnes Salamon, Adrienn Nemes, Miklós Tóth, Márk Juhász, Katalin Lőrinczy, Ágnes Anna Csontos, Pál Miheller
Publikováno v:
Orvosi Hetilap. 154:1821-1828
Vitamin D has an important role in the immune regulation. Vitamin D is essential for innate and adaptive immune systems and it plays a significant role in the formation of immune tolerance, as well.Vitamin D deficiency has been observed in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133da923d580db3bb89047c5f09d0147
https://doi.org/10.1556/oh.2013.29750
https://doi.org/10.1556/oh.2013.29750
Autor:
Kata Szemes, Nelli Farkas, Zoltan Sipos, Renata Bor, Anna Fabian, Zoltan Szepes, Klaudia Farkas, Tamas Molnar, Eszter Schafer, Tamas Szamosi, Agnes Salamon, Aron Vincze, Patricia Sarlos
Publikováno v:
Biomedicines, Vol 12, Iss 1, p 158 (2024)
Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-sele
Externí odkaz:
https://doaj.org/article/b6f609b7b3dc4d84a747938b928dbef9